157 E 32nd St. New York, NY 10016 212-689-6791

Welcome to the Mantle Cell Lymphoma Clinical Trial at MHOA in New York City

Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com

AML- FLT3

Now enrolling of patients on a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are…

Read More

AML- FLT3/IDT

Now enrolling patients for a phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215)…

Read More

CLL

Now enrolling patients for the InformCLL Registry, which is to characterize and describe treatment patterns for those initiating treatment with…

Read More

Hodgkin Lymphoma

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment

Read More